By Ciara Linnane, MarketWatch
Cannabis stocks were lower Tuesday, weighed down by losses in the broader market after the U.S. blacklisted Chinese tech companies, with the collapse of a merger and ending of a supply agreement adding to the gloom.
The Dow Jones Industrial Average /zigman2/quotes/210598065/realtime DJIA +0.80% fell more than 300 points in early trade as trade tensions between China and the U.S. continued to bubble up, with high-level trade talks between the two powers expected to resume on Oct. 10.
Late Monday, the U.S. blacklisted 28 Chinese companies because of their alleged role in human-rights violations against Muslim minorities ahead of the high-level discussions which will be led by China Vice Premier Liu He on Thursday. The S&P 500 /zigman2/quotes/210599714/realtime SPX +0.95% was down 39 points, or 1.4%.
Against that background, the ETFMG Alternative Harvest exchange-traded fund /zigman2/quotes/204332491/composite MJ -2.27% was down 2.4%, with 33 of its 38 constituent stocks declining. The Horizons Marijuana Life Sciences /zigman2/quotes/208856346/delayed CA:HMMJ -3.04% was down 2.4%, with 41 of its 54 member stocks lower.
MedMen Enterprises’s stock /zigman2/quotes/201940908/delayed MMNFF -3.43% slid 6%, after the company said it has terminated its deal to buy PharmaCann LLC. The retailer said a focus on leveraging its retail brand and on its California business would create more shareholder value than completing the acquisition, a stock deal valued at $682 million announced a year ago.
“The cannabis sector has evolved tremendously since we first announced the PharmaCann transaction and based on the current macro-environment and future opportunities that exist for our business, we believe it is now in the best interest of our shareholders to deepen, rather than widen, our company’s reach,” said MedMen Chief Executive Adam Bierman.
MedMen shares have fallen 68% in the last 12 months.
Separately, MedMen said Chief Financial Officer Michael Kramer was terminated on Oct. 7 without providing further details. Kramer will be succeeded by Zeeshan Hyder, who was the company’s chief corporate development officer.
Aleafia Health stock /zigman2/quotes/203485112/delayed ALEAF +2.79% /zigman2/quotes/200214885/delayed CA:ALEF +2.86% slid 5.4% after the company said it has terminated its wholesale cannabis supply agreement with Aphria Inc. /zigman2/quotes/207425803/composite APHA -3.63% /zigman2/quotes/205566616/delayed CA:APHA -3.09% after the latter failed to meet its obligations. The agreement, which dates back to Sept. 11, 2018, was between Aphria and Aleafia-subsidiary Emblem and required that Aphria would provide up to 175,000 kg equivalents of cannabis products over an initial five-year term.
Aphria shares fell 5% on the news. The company said it was disappointed by the move and that it had every intention of fulfilling the deal.
“As a large shareholder of Aleafia, Aphria made good faith efforts to ensure continuation of the agreement understanding it was in the best interest of all parties involved,” said Aphria. It said the parties are contractually required to have 30 days to negotiate, once the termination notice has been received and that if they fail to reach an agreement or settlement, it will fight any effort to claim damages.
Greg McLeish, analyst at Mackie Research, reiterated his buy rating on Aleafia stock and C$3 ($2.25) price target after the news. “Aleafia’s balance sheet remains strong and it exited Q2/19 with cash marketable securities of approximately $63.5 mm,” the analyst wrote in a note to clients.
The lung-disease outbreak that has sickened more than 1,000 people and killed at least 18 across the U.S. and is understood to be related to vaping continues to unsettle cannabis investors, according to Alliance Global Partners. The firm said it recently hosted 25 companies from the cannabis and CBD sectors at a conference and that the health crisis dominated talks.
“While the root cause of these illnesses remains unknown—we believe evidence continues to point to the black market versus the legal market,” analyst Aaron Grey wrote in a note to clients. “ This has still led to an overall impact on the category as Headset data has shown that vape sales mix decreased in adult use markets, but has rebounded recently, which we believe may be an indication of consumers realizing products from the legal market are tested and safer.”